The latest price target for Theriva Biologics (AMEX:TOVX) was reported by Maxim Group on May 8, 2025. The analyst firm set a price target for $0.00 expecting TOVX to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Theriva Biologics (AMEX:TOVX) was provided by Maxim Group, and Theriva Biologics downgraded their hold rating.

There is no last upgrade for Theriva Biologics

The last downgrade for Theriva Biologics Inc happened on May 8, 2025 when Maxim Group changed their price target from N/A to N/A for Theriva Biologics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theriva Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theriva Biologics was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.

While ratings are subjective and will change, the latest Theriva Biologics (TOVX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Theriva Biologics (TOVX) is trading at is $0.55, which is out of the analyst’s predicted range.